Olanzapine orally disintegrating tablet vs. risperidone oral solution in the treatment of acutely agitated psychotic patients

General Hospital Psychiatry

Volumn 30, Issue 4, 2008, Pages 367-371

  Hatta, Kotaro ^a   Kawabata, Toshitaka ^b   Yoshida, Kenichi ^c   Hamakawa, Hiroshi ^d   Wakejima, Toru ^e   Furuta, Ko ^f   Nakamura, Mitsuru ^g   Hirata, Toyoaki ^h   Usui, Chie ^a   Nakamura, Hiroyuki ⁱ   Sawa, Yutaka ^d  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Kyoto Prefectural Rakunan Hospital   (Japan)

^c Chiba Psychiatric Medical Center   (Japan)

^d Sawa Hospital   (Japan)

^e TOKYO METROPOLITAN MATSUZAWA HOSPITAL   (Japan)

^f TOKYO METROPOLITAN TAMA MEDICAL CENTER   (Japan)

^g Toshima Tokyo Metropolitan Hospital   (Japan)

^h Shizuoka Psychiatric Medical Center   (Japan)

ⁱ KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

Agitation; Blood pressure; heart rate; PANSS EC; Psychiatric emergency

Indexed keywords

CHOLINERGIC RECEPTOR STIMULATING AGENT; OLANZAPINE; RISPERIDONE;

ADULT; AGITATION; ANALYSIS OF VARIANCE; ARTICLE; BRADYCARDIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG TOLERABILITY; EMERGENCY HEALTH SERVICE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; HEART RATE; HUMAN; MALE; MULTICENTER STUDY; PATIENT MONITORING; PATIENT SATISFACTION; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TIME; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ACUTE DISEASE; ADMINISTRATION, ORAL; ADULT; ANTIPSYCHOTIC AGENTS; ATTITUDE TO HEALTH; BENZODIAZEPINES; BLOOD PRESSURE; FEMALE; HEART RATE; HUMANS; MALE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR AGITATION; PSYCHOTIC DISORDERS; RISPERIDONE; SOLUTIONS; TABLETS; TACHYCARDIA; TREATMENT OUTCOME;

EID: 45549085098     PISSN: 01638343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2008.03.004     Document Type: Article

References (16)

1. Currier G.W., and Simpson G.M. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J Clin Psychiatry 62 (2001) 153-157
2. Currier G.W., Chou J.C.Y., Feifel D., et al. Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. J Clin Psychiatry 65 (2004) 386-394
3. Allen M.H., Currier G.W., Carpenter D., Roth R., and Docherty J.P. The expert consensus guideline series: treatment of behavioral emergencies 2005. J Psychiatr Pract 11 Suppl 1 (2005) 5-108
4. Currier G.W., and Medori R. Orally versus intramuscularly administered antipsychotic drugs in psychiatric emergencies. J Psychiatr Pract 12 (2006) 30-40
5. Kinon B.J., Hill A.L., Liu H., and Kollack-Walker S. Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia. Int J Neuropsychopharmacol 6 (2003) 97-102
6. Key S.R., Opler L.A., and Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Rating Manual (1991), Multi-Health System Inc, Toronto
7. Breier A., Meehan K., Birkett M., et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 59 (2002) 441-448
8. Kane J.M., Leucht S., Carpenter D., and Docherty J.P. Optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry 64 Suppl 12 (2003) 1-100
9. Guy W. ECDEU Assessment manual for psychopharmacology (1976), US Dept of Health, Education, and Welfare, Bethesda
10. Inada T. Evaluation and diagnosis of drug-induced extrapyramidal symptoms: commentary on the DIEPSS and guide to its usage (1996), Seiwa Shoten Publishers, Tokyo
11. Hatta K., Takahashi T., Nakamura H., Yamashiro H., and Yonezawa Y. Prolonged QT interval in acute psychotic patients. Psychiatry Res 94 (2000) 279-285
12. Rao M.L., Strebel B., Halaris A., et al. Circadian rhythm of vital signs, norepinephrine, epinephrine, thyroid hormones, and cortisol in schizophrenia. Psychiatry Res 57 (1995) 21-39
13. Wagstaff A.J., Easton J., and Scott L.J. Intramuscular olanzapine: a review of its use in the management of acute agitation. CNS Drugs 19 (2005) 148-164
14. Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry 60 Suppl 10 (2000) 5-14
15. Damsa C., Adam E., De Gregorio F., et al. et al: Intramuscular olanzapine in patients with borderline personality disorder: an observational study in an emergency room. Gen Hosp Psychiatry 29 (2007) 51-53
16. San L., Arranz B., Querejeta I., et al. A naturalistic multicenter study of intramuscular olanzapine in the treatment of acutely agitated manic or schizophrenic patients. Eur Psychiatry 21 (2006) 539-543